Research Paper Volume 15, Issue 17 pp 8744—8769
Comprehensive analysis and experimental validation reveal elevated CLCN4 is a promising biomarker in endometrial cancer
Figure 4. Correlation between CLCN4 expression and tumor immune subtypes. Expression of CLCN4 in TISIDB in different tumor immune subtypes. (A) BLCA. (B) BRCA. (C) COAD. (D) GBM. (E) HNSC. (F) KIRC. (G) KIRP. (H) LGG. (I) PCPG. (J) STAD. (K) TGCT. (L) THCA. (M) UCEC. (N) UVM.